Mr. Dean Burns reports

OCUMETICS REPORTS POSITIVE THREE MONTH FIRST-IN-HUMAN RESULTS, SIGNIFICANTLY DE-RISKING ITS ACCOMMODATING INTRAOCULAR LENS TECHNOLOGY

Ocumetics Technology Corp. has released positive three-month postoperative results from group 1 patients in its first-in-human clinical study of the Ocumetics accommodating intraocular lens. The results validate the company's core technology and represent a key clinical derisking milestone as Ocumetics advances toward subsequent study phases.

The group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery and foundational distance visual performance -- achieving the primary objectives required to progress the clinical program.

"These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery and strong visual outcomes," said Dean Burns, president and chief executive officer of Ocumetics.

"Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100 per cent confident in our accommodating intraocular lens technology. Based on this success, we have initiated planning for group 2 surgeries."

Clinical validation and meaningful patient impact

Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250 -- levels consistent with legal blindness. Postimplantation outcomes underscore both the clinical effectiveness and real-world impact of the Ocumetics lens.

"All patient outcomes have met safety expectations," said Dr. Rafael Vazquez, MD, principal investigator of the Ocumetics first-in-human trial. "The profile of the patients I selected had poor vision, and, as a result of the implantations, they have experienced truly a life-changing event. From being classified legally blind, my patients can now read, enjoy everyday life activities and drive. The impact on their independence and sense of freedom has been remarkable," added Dr. Vazquez.

The results from group 1 can be best summarized as follows:

• Safety profile met expectations.
• Visual acuity outcomes met and exceeded expectations.
• Lens delivery system met expectations.

Accelerated path forward

Ocumetics continues to apply its rapid win-learn research and development approach, incorporating surgeon feedback in real time to further optimize performance. Based on insights from group 1, the company has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in group 2.

Manufacturing and testing of optimized lens designs are currently under way. Group 2 surgeries are expected to be scheduled following completion of final lens testing and validation.

"Our group 1 results clearly demonstrated and confirmed the viability of our accommodating intraocular lens technology," concluded Mr. Burns. "This milestone materially strengthens our clinical foundation and positions Ocumetics to build momentum as we advance into group 2. We are excited to continue executing on our clinical and development road map."

Ocumetics webinar

Join Ocumetics director and chief executive officer Dean Burns for an exclusive webinar covering its three-month study results and important updates on its FIH study.

Date:  Wednesday, Feb. 4, 2026

Time:  4 p.m. ET

About Ocumetics Technology Corp.

Ocumetics is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

We seek Safe Harbor.